But competition is actually most central to innovation--and the opposite of what Big Pharma wants.

Competition is crucial to lowering prescription drug prices and improving America's access to lifesaving medication.

I think this period in history right now, which I think is characterized by just unimaginable and unnecessary suffering of immigrants in this country that is a nation of immigrants...

The legislation has a two-fold purpose. First, it will provide the Federal Trade Commission with authority to take action against a manufacturer engaged in product hopping.

The time I believe to act is now.

drug manufacturers are gaming the system to make more money at consumers' expense, and that has to stop.

Instead of truly innovating, drug manufacturers are taking advantage of the anticompetitive environment we have created.

I feel that on this subcommittee where we have a very broad jurisdiction, we have been able to pass some important bills.

It is clear from the testimony that we have heard today that Congress has an opportunity to act to combat the gaming tactics of Big Pharma.

Product hopping or evergreening is the reformulation of a drug by a brand-name manufacturer to delay competition and protect protection for profit.

So we owe it to the American people, and I will be doing everything I can in my power to do so.

But whatever the word or phrase, the bottom line is: drug manufacturers are gaming the system to make more money at consumers' expense.